Amgen tapping China promise as it builds direct presence
This article was originally published in Scrip
Executive Summary
For Amgen, being the world's largest independent biopharmaceutical company is not enough. After having first entered China directly in 2012, setting up a local headquarters in Shanghai, the US firm has now laid out a blueprint to guide its development in this key market over the next few years.